From: Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype
Characteristics | MOG+ ( n = 4) | AQP4+ ( n = 31) | MOG−/AQP4− ( n = 13) |
---|---|---|---|
Sex, female | 3/4 | 23/31 | 8/13 |
Age (years), median (range) | |||
At first attack | 31 (15 to 55) | 38 (15 to 60) | 36 (23 to 53) |
At sampling | 48 (47 to 56) | 46 (20 to 72) | 44 (23 to 66) |
Age at first attack <18 years | 2/4 | 3/31 | 0/13 |
Clinical presentation at first attack | |||
ON (uni-/bilateral) | 2/4 | 16/31 | 8/13 |
TM (%LETM) | 1/4 (100) | 10/31 (90) | 4/13 (100) |
Both | 1/4 | 5/31 | 1/13 |
Second territorial involvement | |||
ON (uni-/bilateral) | 1/4 | 9/31 | 4/13 |
TM (%LETM) | 2/4 (100) | 13/31 (92) | 8/13 (100) |
NMOSD | 0/4 | 4/31 | 0/13 |
None | 1/4 | 5/31 | 1/13 |
Time to second territory involvement (years), mean (range)c | 11.3 (1 to 30) | 3.2 (0 to 9) | 3.4 (0 to 7)a |
EDSS, mean (range) | |||
At sampling | 3.6 (2.5 to 5.0) | 3.0 (0 to 8.0) | 3.5 (0 to 6.5) |
At last follow-up | 3.6 (2.5 to 5.0) | 3.1 (0 to 10.0) | 3.9 (0 to 10) |
CSF, OCB pos. | 3/3a | 5/29b | 1/13 |
MRI brain lesions | 2/4 | 5/31 | 1/13 |
Immunomodulatory treatment | 4/4 | 27/31 | 12/13 |
Clinical follow-up (years), mean (range) | 19 (3 to 35) | 11 (3 to 44) | 9 (2 to 17) |